| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fac65659bfec1cdbccaa51b16b8b1d59 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70575 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate |
2004-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15b233886dcd3452c4887a81b3337130
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39599964f12293099679f35463437d08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1039b2538398c980f9fb56d854bf8ee |
| publicationDate |
2006-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1673389-A2 |
| titleOfInvention |
Novel variants of cd40l protein |
| abstract |
The present invention relates to soluble, recombinant CD40L variant proteins that may be expressed solubly in E. coli. The variants of the present invention may substantially reduced binding to alpha IIb-beta3 integrin, act as CD40L antagonists or agonists, and methods for generating the same. |
| priorityDate |
2003-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |